Novavax, Inc.
Could not find a ticker for this position, may be a filing error
A maker of protein-based vaccines against infectious diseases, this Maryland biotech is best known for Nuvaxovid, its COVID-19 shot that delivers pre-made spike proteins grown in moth cells rather than genetic instructions. Founded in 1987 and spun off from its parent IGI in 1995, it gained its Matrix-M immune-boosting adjuvant by buying Sweden's Isconova in 2013. The name blends "nova" (new) with "vax" (vaccine).
3.75% Convertible Senior Notes due 2023
Granted 483.1K
Granted 135.5K
Granted 180.5K
Granted 125.3K
Granted 112.6K
Granted 36.0K
Granted 36.0K
Granted 75.3K · Sold 61.2K
Granted 6.7K · Sold 25.0K
Granted 43.9K
Granted 47.4K
Granted 40.7K
Granted 36.0K · Sold 4.2K
Granted 2.1K
Granted 14.3K
Granted 9.5K
Granted 7.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Jacobs John CPresident and CEO, Director · 10 transactions | — | 225.7K | 483.1K | — | — |
| O'Hara ElaineEVP, Chief Strategy Officer · 8 transactions | — | 157.1K | 135.5K | — | — |
| Kelly James PatrickEVP, CFO and Treasurer · 16 transactions | +2749% | 130.6K | 180.5K | — | — |
| Casey Mark JEVP, Chief Legal Officer · 8 transactions | — | 101.4K | 125.3K | — | — |
| Trizzino JohnPresident and COO · 12 transactions | +708.4% | 82.0Kas of Mar 2025 | 112.6K | — | — |
| Mott David MDirector · 3 transactions | +82.1% | 79.8K | 36.0K | — | — |
| Douglas RichardDirector · 3 transactions | +96.6% | 73.2K | 36.0K | — | — |
| Dubovsky FilipPresident, R&D · 16 transactions | +55.2% | 66.6Kas of Jun 2024 | 75.3K | — | 61.2K |
| Young James FDirector · 6 transactions | -24.5% | 51.8Kas of Dec 2024 | 6.7K | — | 25.0K |
| Alton Gregg HDirector · 7 transactions | +1154.9% | 47.7K | 43.9K | — | — |
| Rodgers Richard JDirector · 6 transactions | — | 47.4K | 47.4K | — | — |
| McGlynn Margaret GDirector · 7 transactions | +1070.2% | 44.5K | 40.7K | — | — |
| King Rachel K.Director · 4 transactions | +338.5% | 44.1K | 36.0K | — | 4.2K |
| Herrmann John A IIIEVP, Chief Legal Officer · 2 transactions | +11.8% | 17.3Kas of Dec 2023 | 2.1K | — | — |
| Draghia-Akli RuxandraSection 16 · 2 transactions | — | 14.3K | 14.3K | — | — |
| Newton Charles W.Director · 1 transaction | — | 9.5K | 9.5K | — | — |
| Shiver John W.Director · 1 transaction | — | 7.9K | 7.9K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -90.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.